tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

INKT Stock Latest News

MiNK Therapeutics awarded NIAID grant to advance Allo-iNKT cell therapy
The FlyMiNK Therapeutics awarded NIAID grant to advance Allo-iNKT cell therapy
8d ago
INKT
MiNK Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
MiNK Therapeutics Reports Q1 2025 Progress and Financials
25d ago
INKT
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism
PremiumCompany Announcements
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism
25d ago
INKT
Positive Outlook for MiNK Therapeutics: Promising Clinical Developments and Financial Performance
PremiumRatings
Positive Outlook for MiNK Therapeutics: Promising Clinical Developments and Financial Performance
26d ago
INKT
MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating
PremiumRatings
MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating
26d ago
INKT
MiNK Therapeutics reports Q1 EPS (70c) vs ($1.10) last year
PremiumThe FlyMiNK Therapeutics reports Q1 EPS (70c) vs ($1.10) last year
26d ago
INKT
INKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
INKT Upcoming Earnings Report: What to Expect?
28d ago
INKT
MiNK Therapeutics Reports 2024 Progress and Financials
Premium
Company Announcements
MiNK Therapeutics Reports 2024 Progress and Financials
3M ago
INKT
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains
PremiumCompany Announcements
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains
3M ago
INKT
Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion
PremiumRatings
Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion
3M ago
INKT
Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics
PremiumRatings
Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics
3M ago
INKT
Morning Movers: Sarepta slumps after death following Elevidys use
PremiumThe Fly
Morning Movers: Sarepta slumps after death following Elevidys use
3M ago
BTM
BTU
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c)
PremiumThe FlyMiNK Therapeutics reports Q4 EPS (62c), consensus (50c)
3M ago
INKT
Mink Therapeutics, Inc. (INKT) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Mink Therapeutics, Inc. (INKT) Q4 Earnings Cheat Sheet
3M ago
INKT
Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating
Premium
Ratings
Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating
3M ago
INKT
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer
PremiumThe Fly
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer
4M ago
INKT
MiNK Therapeutics regains full compliance with Nasdaq listing requirements
PremiumThe Fly
MiNK Therapeutics regains full compliance with Nasdaq listing requirements
4M ago
INKT
Mink Therapeutics Inc trading halted, news pending
PremiumThe Fly
Mink Therapeutics Inc trading halted, news pending
4M ago
INKT
MiNK Therapeutics price target lowered to $4 from $8 at Baird
PremiumThe Fly
MiNK Therapeutics price target lowered to $4 from $8 at Baird
7M ago
INKT
MiNK Therapeutics Reports Q3 Growth and Strategic Advances
PremiumCompany AnnouncementsMiNK Therapeutics Reports Q3 Growth and Strategic Advances
7M ago
INKT
MiNK Therapeutics reports Q3 EPS (5c), consensus (8c)
Premium
The Fly
MiNK Therapeutics reports Q3 EPS (5c), consensus (8c)
7M ago
INKT
INKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
INKT Upcoming Earnings Report: What to Expect?
7M ago
INKT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >